14 Posts
Repost    Reply    Share 
2/21/2025 1:35:59 PM 
 

CRD-38 Demonstrates Mitochondrial Protection in Preclinical Heart Failure Models
A recent study published in JAC: Basic to Translational Science has unveiled compelling evidence for the efficacy of CRD-38, Cardiol Therapeutics' subcutaneous cannabidiol therapy, in preserving mitochondrial function in heart failure models.
The study demonstrated that CRD-38 effectively mitigates oxidative stress and restores calcium homeostasis, critical factors in maintaining cardiomyocyte health. Read more...
 
 


5 views   Share to: Twitter | LinkedIn | Facebook   Details
 
 
Repost    Reply    Share 
2/21/2025 1:35:22 PM 
 

Cardiol Therapeutics: A Strong Pipeline with Growth Potential
Cardiol Therapeutics (NASDAQ: CRDL) is advancing CBD-based therapies for heart disease, with CardiolRx™ currently in clinical trials for pericarditis and myocarditis. Orphan drug status from the FDA strengthens its path to approval.
Though its stock is down 40%, upcoming clinical results and partnerships could unlock significant value. Read more...
 
 


6 views   Share to: Twitter | LinkedIn | Facebook   Details
 
 
Repost    Reply    Share 
2/21/2025 1:34:44 PM 
 
 
 


9 views   Share to: Twitter | LinkedIn | Facebook   Details
 
 
Repost    Reply    Share 
2/18/2025 1:06:27 PM 
 
 
 


2 views   Share to: Twitter | LinkedIn | Facebook   Details
 
 
Repost    Reply    Share 
2/18/2025 1:03:37 PM 
 
 
 


2 views   Share to: Twitter | LinkedIn | Facebook   Details
 
 

See more posts
Mia Serle's Posts | 40Billion